Collectively, these studies suggest that therapeutic strategies based on the Nrf2–GPX4 signaling axis may open new avenues for PD treatment, providing a multitargeted approach to counteract oxidative damage and ferroptotic cell death. This evidence concerns the gene GPX4 and Parkinson disease.